Abbott Laboratories (NYSE: ABT) VP McCoy receives options and performance stock awards

Rhea-AI Filing Summary

Abbott Laboratories executive John A. McCoy Jr., Vice President and Controller, reported equity awards on February 24, 2026. He acquired an employee stock option for 22,151 options with no purchase price, which vests in three annual installments beginning in 2027. He also received a performance-based restricted stock award of 5,373 common shares that can vest over three years if Abbott meets a minimum return-on-equity target, with shares eligible to be withheld for taxes. Separately, he reported 58 common shares held indirectly in the Abbott Laboratories Stock Retirement Trust as of that date.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider MCCOY JOHN A. JR.

Role VICE PRESIDENT AND CONTROLLER

Type	Security	Shares	Price	Value
Grant/Award	Option (right to buy)	22,151	$0.00	--
Grant/Award	Common shares without par value	5,373	$0.00	--
holding	Common shares without par value	--	--	--

Holdings After Transaction: Option (right to buy) — 22,151 shares (Direct); Common shares without par value — 26,355 shares (Direct); Common shares without par value — 58 shares (Indirect, Profit Sharing Trust)

Footnotes (1)

1. These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Balance in the Abbott Laboratories Stock Retirement Trust as of February 24, 2026. Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 7,383 on February 24, 2027, 7,384 on February 24, 2028, and 7,384 on February 24, 2029.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MCCOY JOHN A. JR.

(Last) (First) (Middle)

100 ABBOTT PARK ROAD

(Street)

ABBOTT PARK IL 60064

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ABBOTT LABORATORIES [ ABT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VICE PRESIDENT AND CONTROLLER

3. Date of Earliest Transaction (Month/Day/Year)
02/24/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common shares without par value	02/24/2026		A		5,373(1)	A	$0	26,355	D
Common shares without par value								58(2)	I	Profit Sharing Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option (right to buy)(3)	$114.6	02/24/2026		A		22,151		02/24/2027	02/23/2036	Common Shares	22,151	$0	22,151	D

Explanation of Responses:

1. These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.

2. Balance in the Abbott Laboratories Stock Retirement Trust as of February 24, 2026.

3. Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 7,383 on February 24, 2027, 7,384 on February 24, 2028, and 7,384 on February 24, 2029.

	/s/ John A. McCoy, Jr. by Jessica H. Paik, Attorney-in-Fact	02/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did ABBOTT LABORATORIES (ABT) report for John A. McCoy Jr.?

John A. McCoy Jr. reported equity award acquisitions, not open-market trades. He received 22,151 stock options and a 5,373-share performance-based restricted stock award, plus disclosed 58 indirect shares in the Abbott Laboratories Stock Retirement Trust as of February 24, 2026.

What are the terms of the 22,151 stock options granted to the ABBT executive?

The 22,151 employee stock options were granted under the Abbott Laboratories 2017 Incentive Stock Program. They become exercisable in annual increments of 7,383, 7,384, and 7,384 on February 24, 2027, February 24, 2028, and February 24, 2029, respectively, in a Rule 16b-3 exempt transaction.

How does the 5,373-share performance-based restricted stock award for ABT work?

The 5,373-share performance-based restricted stock award has a three-year term. No more than one-third can vest in any year, and vesting depends on Abbott achieving a minimum return on equity target. The award also allows shares to be withheld to cover tax obligations.

Did the ABBOTT LABORATORIES insider buy or sell ABT shares on the market?

The filing shows no open-market buys or sells. It reports equity awards granted to the executive—stock options and performance-based restricted shares—plus an indirect holding of 58 shares in a stock retirement trust, rather than regular trading activity.

What is the indirect ownership reported by the ABBT executive in this Form 4?

The executive reported 58 common shares held indirectly through the Abbott Laboratories Stock Retirement Trust. This reflects the balance in the trust as of February 24, 2026, indicating retirement-related share holdings separate from his directly held equity awards.

Under which plan were the ABT options and restricted stock granted to the executive?

Both the stock options and the performance-based restricted stock award were granted under the Abbott Laboratories 2017 Incentive Stock Program. The option grant is described as exempt from Section 16 under Rule 16b-3, indicating it is part of a standard compensation program.